28/73
  • Pages
  • Editions
01 Cover
02 Welcome Letter / Sections
03 Article & Interview Directory
04 Section 1: Introduction
05 Introduction to US Life Sciences
06 Janssen Pharmaceuticals Interview
07 Investment Climate
08 MPM Capital Interview
09 Signet Healthcare Partners Interview
10 Xontogeny Interview
11 Insights from EisnerAmper
12 The Life Sciences Regulatory Climate
13 Buchanan Ingersoll & Rooney PC Interview
14 PhRMA Interview
15 PBOA Interview
16 Ernst & Young LLP Interview
17 LaVoieHealthScience Interview
18 Section 2: Introducing the Hubs
19 East Coast
20 BioNJ Interview
21 MassBio Interview
22 Pennsylvania Biotechnology Center Interview
23 West Coast
24 Biocom California Interview
25 QB3-Berkeley Interview
26 Section 3: Drug Discovery and Development
27 Therapeutic Fields On Fire
28 Insmed Interview
29 Mammoth Biosciences Interview
30 Innovations Enhancing the Patient Experience
31 Arcturus Therapeutics Interview
32 Karius Interview
33 Expert Insights: Targeted Therapeutics
34 First Wave BioPharma Interview
35 Aphios Corporation Interview
36 Section 4: Contract Manufacturing and Chemicals
37 A Shifting Landscape
38 Syngene International Interview
39 Cambrex Interview
40 Lubrizol Life Science Interview
41 Aenova Group Interview
42 Keeping Up With Demands
43 Cureline Interview
44 Interview: Murli Krishna Pharma
45 PsychoGenics Interview
46 Expert Insights: Innovative Technologies
47 AMPAC Fine Chemicals Interview
48 TCG Lifesciences Interview
49 CordenPharma Interview
50 Quotient Sciences Interview
51 A Post-Pandemic World
52 New Vision Pharmaceuticals Interview
53 Adare Pharma Solutions Interview
54 Ascendia Pharmaceuticals Interview
55 Chemicals Producers and Distributors
56 Brenntag North America Interview
57 BASF Pharma Solutions Interview
58 Section 5: Technology Services
59 Life Sciences Go Digital
60 RxS Interview
61 Insights from Markem-Imaje
62 AiCure Interview
63 WhizAI Interview
64 Section 6: Company Profiles
65 Brenntag Company Profile
66 Adare Pharma Solutions Company Profile
67 Quotient Sciences Company Profile
68 SK pharmteco Company Profile
69 AiCure Company Profile
70 Markem-Imaje Company Profile
71 TCG Lifesciences Company Profile
72 Murli Krishna Pharma Company Profile
73 Credits

Will Lewis, Chairman & CEO,

INSMED

"Insmed developed a drug-device combination that became the first approved therapy to treat patients with a refractory form of a rare and serious lung infection."

Could you update our readers on how 2021 was for Insmed?

In 2021, the company expanded upon the growth it experienced in 2020, which had been the most significant year in the company’s history to date. As a company focused on rare diseases, Insmed is currently pursuing four different pillars. Our first pillar and lead program is now approved in the US, Europe and Japan, and has commercially launched. We have advanced our other two development programs, both pulmonary-related, and we added our fourth pillar focused on translational medicine.

Can you provide more insight into the process of bringing your commercial drug to the market?

Insmed developed a drug-device combination that became the first approved therapy to treat patients with a refractory form of a rare and serious lung infection. We are now evaluating this therapy in a frontline patient population, with two clinical trials that are underway.

What is the status of Insmed’s second and third pillars?

The company’s second pillar, brensocatib, is currently in a phase 3 clinical trial as the first investigational DPP1 inhibitor developed for neutrophil-driven inflammatory conditions. We aim to enroll more than 1,600 patients globally in the study to address bronchiectasis, a pulmonary condition that currently has no approved treatments. The drug is unique in that it targets the inflammatory process associated with bronchiectasis rather than the historically unsuccessful approach of treating with anti-infectives. Results from the phase 2 trial were published in the New England Journal of Medicine, the first time in nearly 20 years this journal has published on bronchiectasis. Given the mechanism the drug utilizes, we are evaluating or plan to study it in several other diseases such as cystic fibrosis, chronic rhinosinusitis without nasal polyps, and hidradenitis suppurativa.

Our third pillar is treprostinil palmitil inhalation powder (TPIP), a novel, investigational formulation of prostanoid, a class of drugs used for the treatment of pulmonary arterial hypertension (PAH). PAH is a serious, progressive, rare disease involving narrowing and constriction of the pulmonary arteries, making it difficult for the heart to pump blood effectively. TPIP relaxes the vasculature in a pulmonary setting. We currently have three phase 2 programs underway to evaluate the efficacy of TPIP in PAH and pulmonary hypertension associated with interstitial lung diseases.

What work is Insmed doing in the translational medicine space?

Our fourth pillar is translational medicine. In 2021, Insmed acquired three small companies with teams that are leaders in the fields of gene therapy, protein engineering, and protein manufacturing. This has augmented our existing research capabilities to develop the next generation of medicines utilizing cutting-edge technologies. Insmed wanted to develop an engine that could continuously produce impactful medicines to address rare and serious diseases and write the future of the company. Currently, we have close to 10 pre-clinical programs running and expect to have at least one IND filed every year for the next several years.

Has Insmed faced any supply chain challenges related to Covid-19?

Before the pandemic hit, we had already decided to invest in strengthening our supply chains because we see it as a corporate responsibility to have redundancy within your supply chain if you are in the world of pharmaceuticals. Not all materials are available in the US, so it is important to create inventory supply. We could not have anticipated a global disruption as severe as the pandemic, but our strategy has allowed us to avoid any significant disruptions for Insmed along the way.

The concept of globalization as an unfettered path which everyone is going to pursue has certainly been challenged over the past two years, first with the pandemic and now with increasing geopolitical turmoil. This changes the way companies regard just-in-time production and the origin of raw materials.

Can you elaborate on Insmed’s Investigator-Initiated Research initiative and what it means for the life sciences space?

At Insmed, we follow the science. The idea behind our investigator-initiated research program is to be responsive to key opinion leaders around the world who have ideas for how our therapies may be able to help patients. We want to support innovation in the life sciences ecosystem and will provide financial support and/or product supply for novel research proposals that answer important scientific and medical questions in our areas of interest. In some cases, we will even take on an investigator’s proposed research idea as inspiration for a study of our own.

Next:

Interview: Mammoth Biosciences